Zuventus Healthcare Limited, a leading Indian pharmaceutical company, has issued a formal clarification rejecting rumours and misleading communications suggesting that the company is facing closure or undergoing rebranding.
In a statement issued on Tuesday, Zuventus categorically denied reports of any shutdown, suspension, or transfer of its business assets. The company said its operations continue without interruption and its field staff remains fully functional across the country. It stressed that routine business activities are being carried out at full strength.
The company also clarified that it has no association or affiliation with any entity named Zorvia Healthcare Limited, describing such claims as inaccurate and misleading. Zuventus said the circulation of false information has created unnecessary confusion among stakeholders.
Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its commitment to developing, manufacturing, and marketing high-quality and affordable medicines for patients across India.
Zuventus further stated that it is actively exploring appropriate legal remedies to protect its goodwill and safeguard the interests of its stakeholders against the spread of misinformation.
The company has a strong presence in branded generics, with a diversified portfolio catering to both chronic and acute conditions. Its key therapy areas include cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals. Backed by robust manufacturing standards, a growing field force, and a patient-centric approach, Zuventus said it remains focused on improving health outcomes while building long-term trust with doctors, partners, and patients nationwide.
